Carrier Screening Market Analysis by Sample Type: Blood Leads

 

The global Carrier Screening Market is poised for significant growth, projected to expand from US$ 1.7 billion in 2024 to US$ 5.8 billion by 2035, according to a new industry report titled “Carrier Screening Market (Type: Expanded Carrier Screening, Targeted Disease Carrier Screening; Sample Type: Blood, Saliva, Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025–2035.” The market is expected to grow at a CAGR of 11.8% during the forecast period, fueled by rapid advancements in genetic testing technologies and increasing global awareness of hereditary disorders.

Carrier screening, a key tool in genetic diagnostics, is gaining traction as prospective parents and healthcare providers prioritize early detection and informed reproductive choices. The report underscores the growing adoption of Expanded Carrier Screening (ECS), which tests for over 100 genetic conditions, as a major driver of market expansion. Additionally, blood-based testing continues to dominate due to its superior DNA yield and accuracy, particularly in advanced sequencing techniques such as next-generation sequencing (NGS).

Key Market Drivers:

• Technological Innovations: Integration of NGS, AI, and CRISPR in testing workflows enhances accuracy and efficiency.
• Rising Awareness: Educational campaigns, media, and healthcare initiatives promoting early detection and preventive healthcare.
• Growth in Personalized Medicine: Increased demand for customized genetic testing solutions based on individual risk profiles.

Regional Highlights:

North America led the global market in 2024, thanks to its advanced healthcare infrastructure, high public awareness, and active incorporation of genetic testing into routine care. Major U.S.-based players like Invitae, LabCorp, and GeneDx offer extensive ECS panels and continue to innovate through strategic partnerships and technological upgrades.

Key Players in the Market:

Leading industry participants include Myriad Genetics, Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd, Cepheid, Quest Diagnostics, Fulgent Genetics, Natera Inc., and others. These companies are investing in R&D, enhancing their product offerings, and forming strategic collaborations to strengthen their global footprint.

Recent Developments:

• Illumina launched DRAGEN v4.3 in June 2024, a next-gen sequencing software with AI enhancements and multigenome mapping, supporting deeper genetic insights.
• In March 2023, Illumina Inc. and Myriad Genetics Inc. expanded their partnership to broaden access to oncology HRD testing in the U.S., paving the way for further applications in companion diagnostics.

Market Segmentation Overview:

• By Type: Expanded Carrier Screening, Targeted Disease Carrier Screening
• By Sample Type: Blood, Saliva, Others
• By Technique: DNA Sequencing, PCR, Microarrays, NGS
• By Application: Cystic Fibrosis, Tay-Sachs, Gaucher Disease, Sickle Cell, Others
• By End-User: Hospitals & Clinics, Reference Laboratories, Physician Offices
• By Region: North America, Europe, Asia Pacific, Latin America, Middle East & Africa

This comprehensive report provides stakeholders with valuable insights into emerging trends, growth opportunities, competitive landscape, and regional outlook, enabling informed strategic decisions in the evolving carrier screening landscape.

Visit our report for a deep dive into key insights and conclusions -

https://www.transparencymarketresearch.com/carrier-screening-market-report.html